Current Problems in Cardiology
Volume 32, Issue 4 , Pages 201-259 , April 2007

Systemic Hypertension

References 

  1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560–2572
  2. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223
  4. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:85–151
  5. Hoyert DL, Heron M, Murphy SL, et al. Deaths: Final data for 2003. www.cdc.gov/nchs/products/pubs/pubd/hestats/finaldeaths03/finaldeaths03.htm, 2006.
  6. United States Renal Data System. USRDS 2003 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, July 31, 2003. Also found at: www.usrds.org, accessed 21 February 06 at 19:28 CST.
  7. Glover MJ, Greenlund KJ, Ayala C, et al. Racial/ethnic disparities in prevalence, treatment and control of hypertension—United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005;54:7–9
  8. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–1297
  9. Julius S, Nesbitt SD, Egan B, et al. Feasibility of treating prehypertension with an angiotensin receptor blocker. N Engl J Med. 2006;354:1685–1697
  10. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288:1882–1888
  11. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R Prospective Studies Collaborative. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  12. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–161
  13. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–872
  14. Wang J-G, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;46:907–913
  15. Izzo JL, Levy D, Black HR. Clinical advisory statement: Importance of systolic blood pressure in older Americans. Hypertension. 2000;35:1021–1024
  16. Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869–874
  17. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension. 2002;40:464–469
  18. Jackson R, Lawes CMM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005;365:434–441
  19. MacMahon S, Neal B, Rodgers A. Hypertension—time to move on. Lancet. 2005;365:1108–1109
  20. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320:709–710
  21. Grundy SM, Becker D, Clark LT, et al. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  22. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI Risk Stratification. Hypertension. 2000;34:539–543
  23. Giles T, Berk B, Black HR, et al. Position paper: expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich). 2005;7:505–512
  24. Whitworth JA World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–1992
  25. Zanchetti A, Cifkova R, Fagard R, et al. Guideline Committee 2003 European Society of Hypertension—European Cardiology guidelines for the management of arterial hypertension (Guidelines Committee). J Hypertens. 2003;21:1011–1053
  26. Wallis EJ, Ramsay LE, Haq IU, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ. 2000;320:671–676
  27. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571–1576
  28. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiol. 1999;9:101–107
  29. van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med. 2000;342:1–8
  30. Rogers A, MacMahon S, Yee T, Clark T. Blood pressure, cholesterol, and stroke in eastern Asia: Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet. 1998;352:1801–1807
  31. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–1315
  32. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(suppl 2):3S–10S
  33. Cheung BMY, Ong KL, Man YB, et al. Prevalence, awareness, treatment and control of hypertension: United States National Health and Nutrition Examination Survey, 2001-2002. J Clin Hypertens (Greenwich). 2006;8:93–98
  34. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003–1010
  35. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Hypertension. 1999;34:381–385
  36. Black HR, Kuller LH, O′Rourke MF, et al. The first report of the Systolic and Pulse Pressure (SYPP) Working Group on systolic and pulse pressure. J Hypertens. 1999;17(suppl 5):S3–S14
  37. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–252
  38. Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003;138:10–16
  39. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479–486
  40. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199–203
  41. Gueyffier F, Bulpitt C, Boissel J-P, et al. INDANA Group Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet. 1999;353:793–796
  42. Elliott WJ. Hypertension grand rounds: management of hypertension in the very elderly patient. Hypertension. 2004;44:800–804
  43. Jones CA, Nagpal S. An update: women, hypertension and therapeutic efficacy. Can J Cardiol. 2001;17:1283–1289
  44. Furberg CD, Wright JT, Davis BR, et al. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  45. Turnbull F Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535
  46. Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35:776–785
  47. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292:2849–2859
  48. Hertz RP, Unger AN, Corneel JA, et al. Racial disparities in hypertension prevalence, awareness and management. Arch Intern Med. 2005;165:2098–2104
  49. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141:614–627
  50. Wright JT, Bakris GL, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA. 2002;288:2421–2431
  51. Rehman SU, Hutchison FN, Hendrix K, et al. Ethnic differences in blood pressure control among men at Veterans Affairs clinics and other health care sites. Arch Intern Med. 2005;165:1041–1047
  52. Erdine S. How well is hypertension controlled in Europe?. J Hypertens. 2000;18:1348–1349
  53. Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  54. Weber M, Julius S, Kjeldsen KE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2049–2051
  55. Elliott WJ. Improving the cost-effectiveness of treating hypertension. In:  Epstein M editors. Calcium Antagonists in Clinical Medicine. 3rd Edition. Philadelphia, PA: Hanley & Belfus, Inc; 2002;p. 733–748
  56. Elliott WJ. Economic considerations in the management of hypertension. In:  Izzo JL,  Black HR editor. Hypertension Primer. 3rd Edition. Baltimore, MD: Lippincott, Williams & Wilkins; 2003;p. 317–319
  57. Oparil S, Zaman A, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761–776
  58. Johnson RJ, Rodriguez-Iturbe B, Kang D-H, et al. A unifying pathway for essential hypertension. Am J Hypertens. 2005;18:431–440
  59. Mendelsohn ME. In hypertension, the kidney is not always the heart of the matter. J Clin Invest. 2005;115:840–844
  60. Cowley AW, Roman RJ. The role of the kidney in hypertension. JAMA. 1996;275:1581–1589
  61. O′Brien E. Has conventional syphgmomanometry ended with the banning of mercury?. Blood Press Monit. 2002;7:37–40
  62. Parati G, Asmar R, Stergiou GS. Self blood pressure monitoring at home by wrist devices: a reliable approach?. J Hypertens. 2002;20:573–578
  63. Staessen JA, Den Hond E, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: a randomized controlled trial. JAMA. 2004;291:955–964
  64. Yarows SA, Julius S, Pickering TG. Home blood pressure monitoring. Arch Intern Med. 2000;160:1251–1257
  65. Cappuccio FP, Kerry SM, Forbes L, et al. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ. 2004;329:145
  66. Perloff D, Sokolow M, Cowan RM, et al. Prognostic value of ambulatory blood pressure measurements: Further analyses. J Hypertens. 1989;7(suppl 3):S3–S10
  67. Imai Y, Ohkubo T, Tsuji I, et al. Prognostic value of ambulatory and home blood pressure measurements in comparison to screening blood pressure measurements: a pilot study in Ohasama. Blood Press Monit. 1996;1(suppl 2):51–58
  68. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291:1342–1349
  69. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens. 1998;16:971–975
  70. Rogers MA, Small D, Buchan DA, et al. Home monitoring service improves mean arterial pressure in patients with essential hypertension (A randomized, controlled trial). Ann Intern Med. 2001;134:1024–1032
  71. Broege PA, James GD, Pickering TG. Management of hypertension in the elderly using home blood pressures. Blood Press Monit. 2001;6:139–144
  72. Campo C, Fernandez G, Gonzalez-Estaban J, et al. ESPADA Study Group Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study. Blood Press. 2000;9:355–362
  73. Leeman MJ, Lins RL, Sternon JE, et al. Effect of antihypertensive treatment on office and self-measured blood pressure: The Autodil study. J Human Hypertens. 2000;14:525–529
  74. O’Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821–848
  75. O’Brien E, Beevers G, Lip GYH. ABC of hypertension: blood pressure measurement: Part III—Automated sphygmomanometry: ambulatory blood pressure measurement. BMJ. 2001;322:1110–1114
  76. Tunis S, Kendall P, Londner M, et al. Medicare Coverage Policy—Decisions: Ambulatory Blood Pressure Monitoring (#CAG-00067N): Decision Memorandum. Washington, DC. Health Care Financing Administration, October 17, 2001. Found on the Internet at: www.hcfa.gov/coverage/8b3-ff2.htm; accessed 01 April 02 at 18:32 CST.
  77. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:589–596
  78. Kario K, Pickering TG, Matsuo T, et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38:852–857
  79. Bur A, Herkner H, Vlcek M, et al. Classification of blood pressure levels by ambulatory blood pressure in hypertension. Hypertension. 2002;40:817–822
  80. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–2415
  81. White WB, Larocca GM. Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the “dipping” proportion. Am J Cardiol. 2003;92:1439–1441
  82. Staessen JA, Bieniaszewski L, O’Brien E, et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. Hypertension. 1997;29:30–39
  83. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797–805
  84. Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. J Hypertens. 1998;16:1335–1343
  85. Verdeccia P, Schillaci G, Reboldi G, et al. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation. 2001;103:2579–2584
  86. Verdecchia P, Reboldi G, Porcellati C, et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol. 2002;39:878–885
  87. Kario K, Eguchi K, Hoshide S, et al. U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. J Am Coll Cardiol. 2002;40:133–141
  88. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401–1406
  89. White WB. Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med. 2003;348:2377–2378
  90. Ohkubo T, Imai Y, Tsuji I, et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens. 1997;15:357–364
  91. Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712–718
  92. Pierdomenico SD, Bucci A, Constantini F, et al. Twenty-four hour autonomic nervous function in sustained and “white coat” hypertension. Am Heart J. 2000;140:672–677
  93. Moser M. White-coat hypertension: to treat or not to treat: a clinical dilemma [Editorial]. Arch Intern Med. 2001;161:2655–2656
  94. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of the white coat effect. Hypertension. 1997;29:1218–1224
  95. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203–208
  96. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation. 2000;102:1139–1144
  97. Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. Arch Intern Med. 2000;160:1905–1911
  98. Hansson L, Smith DH, Reeves R, et al. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med. 2000;160:1654–1658
  99. Grimm RH, Grandits GA, Cutler JA, et al. TOMHS Research Group Relationships of quality of life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study (TOMHS). Arch Intern Med. 1997;157:638–648
  100. Wiklund I, Halling K, Ryden-Bergsten T, et al. Does lowering the blood pressure improve the mood? (Quality-of-life results from the Hypertension Optimal Treatment (HOT) study). Blood Press. 1997;6:357–364
  101. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328:634–640
  102. Feldman R Canadian Hypertension Education Program. 2005 Canadian Hypertension Education Program recommendations: what are the new messages?. Perspect Cardiol. 2005;21:30–34
  103. van den Born BJ, Hulsman CA, Hoekstra JB, et al. Value of routine funduscopy in patients with hypertension: systematic review. BMJ. 2005;331:73–76
  104. Turner R, Holman R, Stratton I, et al. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703
  105. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE study group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  106. Abosaif NY, Arije A, Atray NK, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl 1):S1–S290
  107. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006;113:1213–1225
  108. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982–988
  109. Clarke R, Collins R, Lewington S, et al. Homocysteine Studies Collaboration Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–2022
  110. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  111. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med. 2001;345:851–860
  112. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy (Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) Study Group). N Engl J Med. 2001;345:861–869
  113. Safian RD, Textor SC. Medical progress: renal-artery stenosis. N Engl J Med. 2001;344:431–442
  114. Krijnen P, van Jaarsveld BC, Steyerberg EW, et al. A clinical prediction rule for renal artery stenosis. Ann Intern Med. 1998;129:738–740
  115. Krijnen P, Steyerberg EW, Postma CT, et al. Validation of a prediction rule for renal artery stenosis. J Hypertens. 2005;23:1583–1588
  116. Weinrauch LA, D′Elia JA. Renal artery stenosis: “Fortuitous diagnosis,” problematic therapy. [Editorial] J Am Coll Cardiol. 2003;43:1614–1616
  117. Vasbinder GB, Nelemans PJ, Kessels AG, et al. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med. 2001;135:401–411
  118. Vasbinder GBC, Nelemans PJ, Kessels AGH, et al. Renal Artery Diagnostic Imaging Study in Hypertension (RADISH) Study Group Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med. 2004;141:674–682
  119. Bax L, Mali WP, Buskens E, et al. The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal Artery (The STAR-study: rationale and study design). J Nephrol. 2003;16:807–817
  120. Bravo EL. Pheochromocytoma. Cardiol Rev. 2002;10:44–50
  121. Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet. 2005;366:665–675
  122. Kudva YC, Sawka AM, Young WF. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endo Metab. 2003;88:4533–4539
  123. Kaplan NM. Cautions over the current epidemic of primary hyperaldosteronism. Lancet. 2001;357:953–954
  124. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386–394
  125. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary hyperaldosteronism. J Hypertens. 2001;19:353–361
  126. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea and aldosterone: theory and therapy. Hypertension. 2004;43:518–524
  127. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131:485–491
  128. Calhoun DA, Nishizaka MK, Zaman MA, et al. High prevalence of primary hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892–896
  129. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure; an observational study. Lancet. 2005;365:1046–1053
  130. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–884
  131. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials (Implications for public health). J Hum Hypertens. 2002;16:761–770
  132. Whelton PK, Cutler JA, Appel L The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, Phase II. Arch Intern Med. 1997;157:657–667
  133. Whelton PK, Appel LJ, Espeland MA, et al. TONE Collaborative Research Group Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998;279:839–846
  134. Appel LJ, Champagne CM, Harsha DW, et al. Writing Group of the PREMIER Collaborative Research Group Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083–2093
  135. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38:1112–1117
  136. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3–9
  137. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713–724
  138. Elliott WJ, Black HR. The Evidence-Base for Treatment of Hypertension. In:  McInnes GT editors. Handbook of Hypertension, vol. 24: Clinical Pharmacology and Therapeutics of Antihypertensive Drugs. New York, NY: Elsevier; 2007;
  139. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? (A meta-analysis). Lancet. 2005;366:1545–1553
  140. Alderman MA, Furberg CD, Wright JT Antihypertensive and Lipid-lowering treatment to prevent Heart Attack Trial Collaborative Research Group. Diuretic versus α-blocker as first-step antihypertensive therapy (Final results from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)). Hypertension. 2003;42:239–246
  141. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 01 March 2003. J Hypertens. 2003;21:1005–1076
  142. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906
  143. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low dose diuretic therapies. JAMA. 2004;292:43–44
  144. Choi K, Chua D, Elliott WJ. Chlorthalidone vs. other low-dose diuretics. [Letter] JAMA. 2004;292:1816–1817
  145. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616–1628
  146. Khosla N, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochorothiazide equivalent blood pressure-lowering medications?. [Commentary] J Clin Hypertens (Greenwich). 2005;7:354–356
  147. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–358
  148. Burris J, Weir M, Oparil S, et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA. 1990;263:1507–1512
  149. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–886
  150. Liu L, Zhang Y, Liu G, et al. FEVER Study Group The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–2172
  151. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. BMJ. 2000;321:1440–1444
  152. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–124
  153. Stergiou GS, Makris T, Papavasiliou M, et al. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005;23:883–889
  154. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: the HOT Study Group. Lancet. 1998;351:1755–1762
  155. American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care. 2004;27(suppl 1):S1–S153
  156. Raikou M, Gray A, Briggs A, et al. U.K. Prospective Diabetes Study Group Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 1998;317:720–726
  157. Elliott WJ, Weir DR, Black HR. Cost-effectiveness of lowering treatment goal of JNC VI for diabetic hypertensives. Arch Intern Med. 2000;160:1277–1283
  158. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–S154
  159. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease study. Ann Intern Med. 2005;142:342–351
  160. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939–946
  161. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–2033
  162. Agodoa LY, Appel L, Bakris GL, et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728
  163. Gifford RW, August PA, Cunningham GA, et al. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22
  164. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338:701–705
  165. Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69–76
  166. Duley L, Henderson-Smart DJ, Knight M, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2004;CD004659
  167. Haukkamaa L, Salminen M, Laivuori H, et al. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol. 2004;93:805–808
  168. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life (Results from a cohort study). BMJ. 2003;326:845
  169. Falkner B, Roccella E, Daniels SR, et al. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The Fourth Report on the Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004;114:555–576
  170. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411–417
  171. Elliott WJ. Clinical features and management of selected hypertensive emergencies. J Clin Hypertens (Greenwich). 2004;6:587–592
  172. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548–1557
  173. Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management (Part II: therapeutic management and follow-up). Circulation. 2003;108:772–778
  174. Brott T, Bogousslavsky J. Drug therapy: treatment of acute ischemic stroke. N Engl J Med. 2000;343:710–722
  175. Schrader J, Luders S, Kulschewski A, et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699–1703
  176. Elliott WJ. Hypertensive urgencies. In:  Bakris GL editors. The Kidney and Hypertension. London: Martin Dunitz Publishers; 2004;p. 139–152
  177. Grossman E, Ironi AN, Messerli FH. Comparative tolerability profile of hypertensive crises treatments. Drug Safety. 1998;19:99–122
  178. Garg JP, Elliott WJ, Folker A, et al. RUSH University Hypertension Service Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18:619–626
  179. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?. J Neurol Sci. 2005;229-230:151–155

 The author has no conflict of interest to disclose.

PII: S0146-2806(07)00003-5

doi: 10.1016/j.cpcardiol.2007.01.002

Current Problems in Cardiology
Volume 32, Issue 4 , Pages 201-259 , April 2007

Article Tools

* Image Usage & Resolution